Abstract Protein tyrosine phosphatase 1B (PTP1B) is a non-transmembrane protein tyrosine phosphatase that has come into focus as a critical regulator of multiple signaling pathways. The role of PTP1B in breast cancer remains unclear with evidence suggesting that PTP1B can exert both tumor-suppressing and tumor-promoting effects. To better define the role of PTP1B in human breast cancer, and its relationship with HER2, we performed immunohistochemical studies on a large cohort of functionally annotated primary breast cancer specimens. 683 of 1,402 (49 %) evaluable primary breast cancers are positive for PTP1B. There is no statistically significant association between PTP1B expression and age, tumor size, T stage, histologic grade, lymph node status, or histological subtype. Of note, there is no significant association between PTP1B expression and HER2 expression (PTP1B expression 53.1 % in HER2
Introduction
Reversible tyrosine phosphorylation, which is controlled by the opposite actions of protein tyrosine kinases and protein tyrosine phosphatases, constitutes an important mechanism for regulating diverse physiological processes such as cell growth, intercellular communication, cell adhesion, and migration [1, 2] . The protein tyrosine phosphatase 1B (PTP1B) is a non-transmembrane protein tyrosine phosphatase that is located on the cytoplasmic face of the endoplasmic reticulum and has recently come into focus as an important regulator of signaling pathways involved in human diseases such as diabetes, obesity, and cancer [3] . The multiple substrates of PTP1B are associated with diverse cellular processes involving proliferation, apoptosis, intercellular adhesion, and differentiation and include receptor tyrosine kinases, transcription factors, and cytoskeletal proteins [3] . Of note, PTP1B dephosphorylates the insulin receptor and its primary substrates as well as the tyrosine kinase JAK2, a downstream element of the leptin signaling cascade and thus serves as an inhibitor of the insulin and leptin signaling pathways [4] [5] [6] . Other important substrates of PTP1B include the Src homology phosphotyrosyl phosphatase (SHP) 1 and 2, the epithelial growth factor receptor (EGFR), and the platelet-derived growth factor receptor (PDGFR) [1] .
While the biology of PTP1B as a negative regulator of the insulin and leptin signaling pathways has been extensively studied, its role in cancer metabolism remains unclear. Experimental evidence suggests that PTP1B can exert both tumor-suppressing and tumor-promoting effects. As many oncogenes encode proteins with a tyrosine kinase activity that appears to be directly involved in the process of transformation, overexpression of protein tyrosine phosphatases, which remove phosphate from tyrosine residues, are intuitive tumor suppressors. Consistent with this hypothesis, studies have shown that PTP1B overexpression diminishes tumorigenecity in transformed mouse fibroblasts [7, 8] , and several reports suggest that PTP1B can promote apoptosis through down-regulation of pro-survival signaling [9, 10] , enhancement of stress signaling [11] , or facilitation of caspase activities [3, 12] . Consistent with this hypothesis is the finding that p53 and PTP1B double knockout mice show an increase of B cell lymphomas and a decreased survival when compared to p53-only knockout mice [13] .
In contrast to these findings, there is evidence that PTP1B might act as a tumor promoter. For example, upregulation of PTP1B was associated with increased tumor growth in colon cancer cell lines [14] , and it has been shown that PTP1B is able to block anti-tumor signaling pathways in carcinoma and lymphoma cell lines [15] . Additional evidence for a role of PTP1B in promoting tumorigenesis has come from studies of human cancers. Immunohistochemical studies looking at the expression of PTP1B in tumor cells found that it was upregulated in 80 % of ovarian carcinomas [16] and also elevated in squamous cell carcinomas when compared to normal human skin [17] . In addition, a recent report by Lessard et al. [18] suggests a tumor-promoting role of PTP1B in human prostate cancer.
The role of PTP1B has been studied most extensively in breast cancer, with several studies focused on the potential association of PTP1B with the human epidermal growth factor receptor 2 (HER2), and the potential for PTP1B to modulate HER2 signaling. In an important study by Wiener et al. [19] , 21 out of 29 human breast cancers stained strongly for PTP1B when compared to normal breast tissue, and overexpression of PTP1B was noted in 11 out of 12 HER2
? cases. This strong association between PTP1B and HER2 expression suggests that PTP1B and HER2 may cooperate in the pathogenesis of this subtype of breast cancers. Two recent studies independently support this hypothesis, showing that PTP1B deficiency delays tumor progression and protects against lung metastasis in an activated HER2-induced genetically engineered mouse model of human breast cancer [20, 21] . In this model, both genetic deletion of PTP1B activity in the NDL2 transgenic mice, as well as chemical inhibition of PTP1B, delayed the time of tumor onset [20] . Importantly, PTP1B-deficient mice were not universally protected against the development of mammary tumors, as mammary tumors actuated by the polyoma middle T antigen were not affected by loss of PTP1B [21] . PTP1B therefore seems to have a selective affirmatory role in HER2 signaling [22] , and even seems to be required for HER2-dependent transformation of human breast epithelial cells [23] . In contrast, in an older study, it was shown that PTP1B was capable of suppressing oncogenic transformation by HER2 [8] . Supporting a possible oncogenic role of PTP1B in breast cancer is the finding that overexpression of PTP1B in the mouse mammary gland leads to spontaneous mammary tumor development, suggesting that this tyrosine phosphatase can act as an oncogene on its own [20] . In humans, overexpression of PTP1B in breast epithelial cells distorts the normal acinar morphology and causes uninhibited proliferation and loss of polarity [23] .
The pharmaceutical industry has developed a considerable interest in PTP1B as a potential drug target, as its inhibition might help control a number of common diseases such as adult-onset diabetes and obesity. Based on the studies reviewed above highlighting a potential role for PTP1B in HER2-mediated breast cancer, investigators have also proposed targeting this molecule in human breast cancer. To further explore the role of PTP1B in human breast cancer, we conducted an immunohistochemical study on a breast cancer tissue microarray (TMA) encompassing a total of 1,402 formalin-fixed breast cancer cases with detailed clinical annotation and outcomes data. The aim of our study was to investigate the association between PTP1B and HER2 and other clinicopathological parameters in breast cancer, and to study the impact of PTP1B on prognosis. The data are reported according to the Reporting recommendations for tumor marker prognostic studies (REMARK) [24] .
Materials and methods

Tissue microarray
We used a TMA encompassing 2,020 breast cancer tissue punches from 1,579 formalin-fixed and paraffin-embedded tumor samples collected from patients diagnosed with primary breast cancer between 1985 and 2007 at the Institute for Pathology, University of Basel and the Viollier Institute in Basel, Switzerland. Of these 2,020 tissue punches, a total of 1,402 were evaluable for our study. The tissue samples were brought into a TMA format as previously described [25] . In brief, 0.6-mm tissue cylinders were punched out of donor tumor tissue blocks and transferred into a recipient paraffin block using a semi-automated tissue arrayer. Each TMA contained a number of tumor punches ranging from 159 to 522. Histopathological data were obtained from the pathology reports, and raw patient survival data were obtained from the Cancer Registry of Basel or from the patient's attending physician. Retrieval of tissue and clinical data was performed according to the regulations of the local institutional review boards and data safety laws with specific regard to ethical standards and patient confidentiality. The mean follow-up time was 80.8 months (range 1-263 months), and the median age of the patients was 63 years (range 27-101 years). Demographic information of the patients can be found in Table 1 .
Immunohistochemistry
For immunohistochemical staining, 4-lm sections of the TMA blocks were incubated overnight with the primary monoclonal anti-PTP1B antibody (Epitomics Inc., Catalog Nr. 2066-1, CA, USA) in a dilution of 1:200 after heatinduced antigen retrieval with Citrate buffer at pH 6. Standard DAB technique (Dako EnVision ? Systemlabeled Polymer Anti-rabbit followed by Liquid DAB ? Substrate Chromogen System) was employed for immunostaining. Counterstaining was performed with hematoxylin solution. The percentage of cells with a distinctive strong cytoplasmic staining was estimated. All cases with a cytoplasmic PTP1B expression of C5 % were considered positive for PTP1B expression. The staining intensity of ER, PR, and HER2 was scored as described previously [26] . In brief, tumors were considered positive for ER if they showed nuclear staining in more than 10 % of tumor cells with an intensity score between 1 and 3.
Statistical analysis
The distributions of patient and clinical characteristics between PTP1B-positive and PTP1B-negative tumors were compared using Chi-square test, Wilcoxon rank sum test, or two-sample t test, as appropriate. The strength of association between PTP1B expression and other continuous or ordinal factors (such as tumor size and ER expression) was also described using Spearman's correlation coefficients (q). Overall survival (OS) was defined as the time from the first operation to death due to any cause. Survivors were censored at the date of last contact. Survival curves by PTP1B status were estimated using the Kaplan-Meier product-limit method and compared by log-rank test. Univariate Cox proportional hazard models were fit to identify factors significantly related to OS. To assess whether PTP1B was an independent predictor of survival, a multivariate Cox model was constructed to adjust other patient/clinical characteristics that were significant in the univariate analyses. Two-way interaction terms between PTP1B and other factors in the multivariate Cox model were also assessed. All analyses were two-sided and significance was set at a p value of 0.05. Statistical analyses were performed using SAS (SAS Institutes, Cary, NC). 
Results
Consistent with the known intracellular localization of PTP1B, breast cancers expressing PTP1B showed strong cytoplasmic staining of PTP1B (Fig. 1) . Using a threshold of C5 % of cancer cells staining positive for PTP1B, a total of 683 (49 %) of the 1,402 evaluable primary breast cancers were positive for PTP1B. PTP1B expression was not significantly associated with tumor size, age at diagnosis, tumor stage, tumor grade, lymph node status ( cancers vs. 47.5 % in HER2 -cancers, p = 0.0985, and Spearman's q = -0.04, Table 2 ). However, we did find a small, but statistically significant association between PTP1B expression and ER status (PTP1B expression 50.7 % in ER ? cancers vs. 43.1 % in ER -cancers, p = 0.0137, and Spearman's q = -0.07, Table 2 ). In addition, PTP1B expression is associated with the intrinsic subtypes of breast cancer, as defined by the St. Gallen consensus conference. The breast cancer intrinsic subtypes were originally defined by gene expression profiling [27, 28] but can be approximated using immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR), Ki-67, and HER2 [29, 30] . These subtypes are known to have differing epidemiological risk factors, prognosis, and response to therapy [29] . PTP1B expression was highest in the luminal B HER2
? subtype (53.9 %) and lowest in the basal-like subtype (37.9 %, p = 0.008) ( Table 3) .
Studying the impact of PTP1B expression on survival, we found that in univariate survival analyses, breast cancer cases with positive PTP1B expression had a significantly better OS (hazard ratio (HR) = 0.763, p = 0.002) ( Table 4 ; Fig. 2) . In multivariate analyses, after adjusting for age, grade, tumor size, lymph node status, and intrinsic subtype, PTP1B remained an independent positive prognostic factor for OS (HR = 0.779, p = 0.006) ( Table 5 ). In subset analyses of the specific intrinsic subtypes, PTP1B expression proved to be an independent prognostic factor for OS in the luminal B HER2
-type, where positive PTP1B expression was associated with significantly better OS (HR = 0.661, p = 0.002) ( Table 4 ; Fig. 3 ). The luminal A subtype also showed a strong trend toward improved OS with PTP1B expression (HR = 0.568, p = 0.051) ( Table 4 ; Fig. 3 ), but this was not statistically significant. Of note, PTP1B expression did not have a significant impact on OS in HER2
? cases (Table 4 ; Fig. 5 ). Fig. 4 ).
Discussion
In our study, we evaluated the expression of PTP1B in a large cohort of functionally annotated primary breast cancer specimens. We observed that PTP1B is expressed in 49 % of primary breast cancers. This is in contrast to the report by Wiener et al. [19] , who observed PTP1B expression in 73 % of primary breast cancers. Their collective, however, was fairly small (n = 29), and the authors used a different evaluation system where they assigned expression intensities of 0-3 ? to the tissues and considered 2 ? and 3 ? as positive. The authors also used a non-commercially available antibody which consists of a different clone, which could have led to a different staining pattern. As all our positive cases showed a strong staining intensity of 3 ? , we decided to estimate the percentage of positive cells and to take all cases that showed cytoplasmic staining C5 % of cancer cells as positive.
Our results show that expression of PTP1B in primary breast cancers is associated with significantly better OS. Therefore, in contrast to the experience with murine models of breast cancer, PTP1B appears to play a tumorsuppressive role in human breast cancer. This may be through dephosphorylation of dysregulated protein tyrosine kinases and concomitant inhibition of oncogenic signaling pathways. One well-described substrate for PTP1B is EGFR, a protein that is associated with worse OS in breast cancer and has recently been implicated in the promotion of breast cancer brain metastases [31, 32] . It could be that PTP1B plays a role in the dephosphorylation of EGFR in breast cancer, limiting invasion and migration of breast cancer cells. In fact, several studies have shown that PTP1B is able to strengthen and stabilize cell-cell adhesion [33, 34] . Alternatively, the effect of PTP1B on breast cancer could be mediated through the modulation of other signaling pathways. For example, several reports suggest Fig. 3 Kaplan-Meier survival curve for OS depending on PTP1B expression for the intrinsic breast cancer subtypes. PTP1B expression is an independent prognostic factor for OS in the luminal B HER2 -type. The luminal A subtype also showed a strong trend toward improved OS with PTP1B expression that PTP1B promotes apoptosis through down-regulation of pro-survival signaling [9, 10, 12] .
The study by Wiener et al. [19] showed a significant correlation between the expression of PTP1B and HER2, an observation that was not replicated in our larger cohort of 1,402 evaluable cases. As such, our data does not support the hypothesis put forward by several studies suggesting that there is a biologic association, and possible functional interaction, between these two proteins in breast cancer [19] [20] [21] 23] . We did observe a small positive correlation between the expression of PTP1B and ER in our series, and PTP1B expression had a significant positive effect on OS in ER ? , but not ER -patients. This association has not been described in the literature to date, and the mechanisms linking ER to PTP1B have yet to be investigated.
The pharmaceutical industry has long focused on PTP1B as a potential therapeutic target for diabetes and obesity. Several companies have created potent and selective PTP1B inhibitors, and the question has been raised whether these inhibitors could also be used in breast cancer therapy [22, 35] , particularly for HER2
? breast cancers [35] . Our results, however, suggest that (1) expression of PTP1B in human breast cancer might represent a favorable condition and (2) PTP1B may not have any functional implication in human HER2
? breast cancers. Further studies investigating the functional mechanisms of PTP1B in breast cancer are needed. Until we know more about the role of this enzyme in human breast cancer, caution should be exercised in using PTP1B inhibitors in a clinical setting with breast cancer patients.
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